We would love to hear your thoughts about our site and services, please take our survey here.
So it seems they’ve done the disposal to get things moving with superapps.. probably building/developing app back end.
merger still to go to vote as before between TETE / Superapps .. which concerns the cash payments to MBO.
it’s as we were .. but with TETE making a move..
They’ve disposed the 60%. Probably so both parties can begin developing on superapps (there’s jobs on mbo careers section for software engineers with code SUPP-APP)
So, if merger goes ahead the payment terms stand as before.
If it doesn’t, the 60% disposal can be taken back for a nominal value.
Its an “as you were” RNS in reality.
We await merger and further news
It doesn’t matter how many times you say this over and over again it will keep happening on aim Dave. It’s been happening since day dot., just market is so illiquid now it’s harder for folk who try it.
Anyway., let’s keep it positive on MBO. We can’t control the numpties buy and sell buttons
It’s difficult to put a real value to this until we see the scale of next commercial deals.
But, for me.. the value here lies in this as a takeout target. Read between the lines at what Thermofisher are using that belongs to VRCI.
Companies like TMO could take us out for several multiples with change they find under their sofa cushions. This is such a gem..
“Global licensing and commercialisation agreement with Thermo Fisher Scientific
Commercial agreement for exclusive license to Verici Dx Assay Technology”
Https://x.com/hati_intl/status/1762431418414596456?s=46
#HATIInternational is going global! With a focus on seamless healthcare payments and expanding our #IoT/#AI tech, we're ready to make waves beyond #Malaysia. Thanks to our amazing team, partners, and #MobilityOne for believing in our mission! 🌐
#HealthcareInnovation
Looking much better. I wonder where these buyers have come from? Hopefully just others noticing the SEC filings / declarations from institutions..
https://www.nasdaq.com/market-activity/stocks/tete/sec-filings
“The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.”
So on point in current times. Easy takeout target imo.
Interesting codes on a new job listing on MBO’s website .. in the careers section
SOFTWARE ENGINEER (CODE: SE-SUPP-APP)
SNR SOFTWARE ENGINEER (CODE: SSE-SUPP-APP)
"MobilityOne runs a number of e-services for electronic payment, prepaid reload, bill payment and remittance services. These services are integrated to multiple Banks, Telcos, SMEs and Service Providers to provide end Customers with a convenient mechanism for effecting electronic payment, purchase and remittance transactions."
https://www.mobilityone.com.my//v4/pages/pdf/ApplicationSupportEngineer.pdf